M&A isn't an Rx for big pharma

Drugs and deal making are a potent combination. But, for the first time in years, big pharma can find reasons to go it alone

Drugs and deal making are a potent combination.

But, after a series of deals that include Actavis buying Warner Chilcott for $5bn and Valeant buying private equity-owned Bausch & Lomb for $8.7bn, bankers and investors shouldn't get hooked. For the first time in years, Big Pharma can find reasons to go it alone.

WSJ Logo
Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With TrumpExternal link

Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With Trump